Wave Life Sciences (NASDAQ:WVE) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Wave Life Sciences (NASDAQ:WVE) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $22.00 price target on the stock.

Several other analysts have also recently commented on WVE. Mizuho lifted their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Jefferies Financial Group started coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective for the company. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, February 27th. Finally, Truist Financial lifted their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, November 12th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.60.

Wave Life Sciences Trading Down 5.9 %

Shares of NASDAQ WVE opened at $10.57 on Wednesday. Wave Life Sciences has a 12 month low of $4.25 and a 12 month high of $16.74. The company has a 50 day simple moving average of $11.58 and a two-hundred day simple moving average of $11.19. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -9.52 and a beta of -1.09.

Institutional Investors Weigh In On Wave Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in Wave Life Sciences by 23.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after acquiring an additional 856 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Wave Life Sciences by 16.6% in the 4th quarter. Victory Capital Management Inc. now owns 14,546 shares of the company’s stock worth $180,000 after acquiring an additional 2,073 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after acquiring an additional 2,308 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Wave Life Sciences in the 4th quarter worth $40,000. Finally, Kraematon Investment Advisors Inc. increased its holdings in Wave Life Sciences by 24.3% in the 4th quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company’s stock worth $246,000 after acquiring an additional 3,885 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.